Skip to main content

Combination Strategies

Section edited by Paolo A. Ascierto

This section aims to provide a focal point for research that highlights combination therapies, where two or more medications or therapies are strategically combined to improve the treatment of cancer, chronic infections, transplantation and potentially other complex and multi-factorial diseases.

Increasingly detailed understanding of the molecular basis driving complex disease has led to the identifications of new agents that target specific pathways. In some cases treatment of appropriately selected patients has led to striking clinical response, however both primary and secondary resistance mechanisms limited the success of many of these agents. It has become clear that combining or sequencing treatment modalities may enrich the communication between basic biological and immunological sciences and the clinical investigation arena.

Featured articles

Why tocilizumab could be an effective treatment for severe COVID-19?

Commentary | Binqing Fu et al


SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines

Commentary | Giovanni Salvatori et al


Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection

Research | Jing Zhang ​​​​​​​et al

Page 1 of 4

  1. Nonthyroidal Illness Syndrome (NTIS) can be detected in many critical illnesses. Recently, we demonstrated that this condition is frequently observed in COVID-19 patients too and it is correlated with the seve...

    Authors: Salvatore Sciacchitano, Carlo Capalbo, Christian Napoli, Andrea Negro, Luciano De Biase, Adriano Marcolongo, Paolo Anibaldi, Valentina Salvati, Lea Petrella, Luca Merlo, Daniela Alampi, Elisa Alessandri, Chiara Loffredo, Alessandra Ulivieri, Luca Lavra, Fiorenza Magi…

    Citation: Journal of Translational Medicine 2021 19:491

    Content type: Research

    Published on:

  2. Overweight and obese patients with solid tumors receiving anti-programmed cell death-1 (PD-1)/PD-ligand-1(PD-L1) immune checkpoint inhibitors exhibit improved survival and higher risk of immune-related adverse ev...

    Authors: Rosaria De Filippi, Fortunato Morabito, Armando Santoro, Giovanni Tripepi, Francesco D’Alò, Luigi Rigacci, Francesca Ricci, Emanuela Morelli, Pier Luigi Zinzani and Antonio Pinto

    Citation: Journal of Translational Medicine 2021 19:489

    Content type: Research

    Published on:

  3. Sarcoidosis is an inflammatory disease characterized by the formation of granulomas, which involve the heart in up to 25% of patients. Cardiac sarcoidosis can lead to life threatening arrhythmias and heart fai...

    Authors: Jordana Kron, Thomas Crawford, Virginia Mihalick, Frank Bogun, Jennifer H. Jordan, Todd Koelling, Huzaefah Syed, Aamer Syed, Thomas Iden, Kelly Polly, Emily Federmann, Kirsta Bray, Sangeeta Lathkar-Pradhan, Shilpa Jasti, Lynda Rosenfeld, David Birnie…

    Citation: Journal of Translational Medicine 2021 19:460

    Content type: Protocol

    Published on:

  4. Immune checkpoint blockades (ICBs) therapy showed limited efficacy in ovarian cancer management. Increasing evidence indicated that conventional and targeted therapies could affect tumor-associated immune resp...

    Authors: Jinyu Meng, Jin Peng, Jie Feng, Jochen Maurer, Xiao Li, Yan Li, Shu Yao, Ran Chu, Xiyu Pan, Junting Li, Ting Zhang, Lu Liu, Qing Zhang, Zeng Yuan, Hualei Bu, Kun Song…

    Citation: Journal of Translational Medicine 2021 19:415

    Content type: Research

    Published on:

  5. The purpose of this study was to evaluate if HPV status serves as an independent predictor of early and late dysphagia outcomes when considered alongside standard patient characteristics and dose metrics for h...

    Authors: Xenia Ray, Whitney Sumner, Leisa Sutton, Parag Sanghvi, Ida Deichaite and Vitali Moiseenko

    Citation: Journal of Translational Medicine 2021 19:380

    Content type: Research

    Published on:

  6. Recently, convalescent plasma (CP) transfusion was employed for severe or critically ill patients with coronavirus disease-2019. However, the benefits of CP for patients with different conditions are still in ...

    Authors: Li Huang, Che Zhang, Xihui Zhou, Zhou Zhao, Weiping Wang, Weidong Leng, Xiao Su and Qizhou Lian

    Citation: Journal of Translational Medicine 2021 19:365

    Content type: Research

    Published on:

  7. Severe immune-related Adverse Events (irAEs) develop in 10–27% of patients treated with Immune-Oncology (IO) [Powles (Lancet 391:748–757, 2018); Galsky (Lancet 395:1547–1557, 2020); Haanen (Ann Oncol 28:119–14...

    Authors: Marco Stellato, Giuseppe Procopio, Ugo De Giorgi, Marco Maruzzo, Davide Bimbatti, Alessia Mennitto, Andrea Sbrana, Giandomenico Roviello, Chiara Casadei, Pierangela Sepe, Sandro Pignata and Daniele Santini

    Citation: Journal of Translational Medicine 2021 19:328

    Content type: Research

    Published on:

  8. First-line therapy for metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) has been revolutionized by the introduction of anti-checkpoint monoclonal antibodies, which have shown a significant i...

    Authors: Andrea Botticelli, Giulia Pomati, Alessio Cirillo, Giulia Mammone, Fabio Ciurluini, Bruna Cerbelli, Paolo Sciattella, Massimo Ralli, Umberto Romeo, Francesca De Felice, Carlo Catalano, Francesco Vullo, Marco Della Monaca, Sasan Amirhassankhani, Silverio Tomao, Valentino Valentini…

    Citation: Journal of Translational Medicine 2021 19:303

    Content type: Research

    Published on:

  9. Advances in immune checkpoint therapy and targeted therapy have led to improvement in overall survival for patients with advanced melanoma. Single agent checkpoint PD-1 blockade and combination with BRAF/MEK t...

    Authors: Paolo A. Ascierto, Christian Blank, Reinhard Dummer, Marc S. Ernstoff, Soldano Ferrone, Bernard A. Fox, Thomas F. Gajewski, Claus Garbe, Patrick Hwu, Pawel Kalinski, Michelle Krogsgaard, Roger S. Lo, Jason J. Luke, Bart Neyns, Michael A. Postow, Sergio A. Quezada…

    Citation: Journal of Translational Medicine 2021 19:278

    Content type: Meeting report

    Published on:

  10. The favourable safety profile and the increasing confidence with immune checkpoint inhibitors (ICIs) might have boosted their prescription in frail patients with short life expectancies, who usually are not tr...

    Authors: Daniele Santini, Tea Zeppola, Marco Russano, Fabrizio Citarella, Cecilia Anesi, Sebastiano Buti, Marco Tucci, Alessandro Russo, Maria Chiara Sergi, Vincenzo Adamo, Luigia S. Stucci, Melissa Bersanelli, Giulia Mazzaschi, Francesco Spagnolo, Francesca Rastelli, Francesca Chiara Giorgi…

    Citation: Journal of Translational Medicine 2021 19:270

    Content type: Research

    Published on:

  11. We aimed to develop a radiomic model based on pre-treatment computed tomography (CT) to predict the pathological complete response (pCR) in patients with rectal cancer after neoadjuvant treatment and tried to ...

    Authors: Zhuokai Zhuang, Zongchao Liu, Juan Li, Xiaolin Wang, Peiyi Xie, Fei Xiong, Jiancong Hu, Xiaochun Meng, Meijin Huang, Yanhong Deng, Ping Lan, Huichuan Yu and Yanxin Luo

    Citation: Journal of Translational Medicine 2021 19:256

    Content type: Research

    Published on:

  12. Optimizing the therapeutic ratio for radiation therapy (RT) in head and neck squamous cell carcinoma (HNSCC) is uniquely challenging owing to high rates of early and late toxicity involving nearby organs at ri...

    Authors: Whitney Sumner, Xenia Ray, Leisa Sutton, Daniel Rebibo, Francesco Marincola, Parag Sanghvi, Vitali Moiseenko and Ida Deichaite

    Citation: Journal of Translational Medicine 2021 19:212

    Content type: Research

    Published on:

  13. Aberrant PI3K signalling is implicated in trastuzumab resistance in HER2-positive gastric cancer (GC). The role of PI3K or MEK inhibitors in sensitising HER2-positive GCs to trastuzumab or in overcoming trastu...

    Authors: M. Janusz Mezynski, Angela M. Farrelly, Mattia Cremona, Aoife Carr, Clare Morgan, Julie Workman, Paul Armstrong, Jennifer McAuley, Stephen Madden, Joanna Fay, Katherine M. Sheehan, Elaine W. Kay, Ciara Holohan, Yasir Elamin, Shereen Rafee, Patrick G. Morris…

    Citation: Journal of Translational Medicine 2021 19:184

    Content type: Research

    Published on:

  14. Sarcomas are rare, ubiquitous and heterogeneous tumors usually treated with surgery, chemotherapy, target therapy, and radiotherapy. However, 25–50% of patients experience local relapses and/or distant metasta...

    Authors: Ottavia Clemente, Alessandro Ottaiano, Giuseppe Di Lorenzo, Alessandra Bracigliano, Sabrina Lamia, Lucia Cannella, Antonio Pizzolorusso, Massimiliano Di Marzo, Mariachiara Santorsola, Annarosaria De Chiara, Flavio Fazioli and Salvatore Tafuto

    Citation: Journal of Translational Medicine 2021 19:173

    Content type: Review

    Published on:

  15. Lactate dehydrogenase A (LDHA) is overexpressed and associated with poor prognosis in many kinds of cancer. In the current study, we evaluated the prognostic value of LDHA expression in non-small cell lung cancer...

    Authors: Yang Yang, Yu Chong, Mengyuan Chen, Wumin Dai, Xia Zhou, Yongling Ji, Guoqin Qiu and Xianghui Du

    Citation: Journal of Translational Medicine 2021 19:170

    Content type: Research

    Published on:

  16. Gut microbiota has been reported to be disrupted by cisplatin, as well as to modulate chemotherapy toxicity. However, the precise role of intestinal microbiota in the pathogenesis of cisplatin hepatotoxicity r...

    Authors: Shenhai Gong, Yinglin Feng, Yunong Zeng, Huanrui Zhang, Meiping Pan, Fangjie He, Rong Wu, Jingrui Chen, Jiuling Lu, Siyou Zhang, Songhua Yuan and Xia Chen

    Citation: Journal of Translational Medicine 2021 19:147

    Content type: Research

    Published on:

  17. The Great Debate session at the 2020 Melanoma Bridge virtual congress (December 3rd–5th, Italy) featured counterpoint views from experts on five specific controversial issues in melanoma. The debates considere...

    Authors: Paolo A. Ascierto, Michael B. Atkins, Alexander M. Eggermont, Jeffrey E. Gershenwald, Jean-Jacques Grob, Omid Hamid, Vernon K. Sondak, Jeffrey A. Sosman, Hussein A. Tawbi, Jeffrey S. Weber, Corrado Caracò, Iman Osman and Igor Puzanov

    Citation: Journal of Translational Medicine 2021 19:142

    Content type: Meeting report

    Published on:

  18. Coronavirus disease 2019 (COVID-19) global pandemic has created unique challenges to healthcare systems throughout the world. Ensuring subjects’ safety is mandatory especially in oncology, in consideration of ...

    Authors: Maria Antonietta Isgrò, Maria Grazia Vitale, Egidio Celentano, Flavia Nocerino, Giuseppe Porciello, Marcello Curvietto, Domenico Mallardo, Concetta Montagnese, Luigi Russo, Nicoletta Zanaletti, Antonio Avallone, Matilde Pensabene, Michelino De Laurentiis, Sara Centonze, Sandro Pignata, Lucia Cannella…

    Citation: Journal of Translational Medicine 2021 19:132

    Content type: Research

    Published on:

  19. The response to immunotherapy can be impaired by several factors including external intervention such as drug interactions with immune system. We aimed to examine the immunomodulatory action of opioids, since ...

    Authors: Andrea Botticelli, Alessio Cirillo, Giulia Pomati, Bruna Cerbelli, Simone Scagnoli, Michela Roberto, Alain Gelibter, Giulia Mammone, Maria Letizia Calandrella, Edoardo Cerbelli, Francesca Romana Di Pietro, Federica De Galitiis, Gaetano Lanzetta, Enrico Cortesi, Silvia Mezi and Paolo Marchetti

    Citation: Journal of Translational Medicine 2021 19:119

    Content type: Research

    Published on:

    The Letter to the Editor to this article has been published in Journal of Translational Medicine 2021 19:160

  20. Exosomes are nanoparticle sized (100 ± 50 nm) extracellular vesicles (ECVs) that play important roles in cell-to-cell communication. They do this by utilizing their natural ability to shuttle signaling molecul...

    Authors: Michael J. Gonzalez, Mercedes F. Kweh, Pier Mario Biava, Jose Olalde, Alondra P. Toro, Pascal J. Goldschmidt-Clermont and Ian A. White

    Citation: Journal of Translational Medicine 2021 19:103

    Content type: Review

    Published on:

  21. The Sars-CoV-2 can cause severe pneumonia with multiorgan disease; thus, the identification of clinical and laboratory predictors of the progression towards severe and fatal forms of this illness is needed. He...

    Authors: Flavia Biamonte, Cirino Botta, Maria Mazzitelli, Salvatore Rotundo, Enrico Maria Trecarichi, Daniela Foti, Carlo Torti, Giuseppe Viglietto, Daniele Torella and Francesco Costanzo

    Citation: Journal of Translational Medicine 2021 19:79

    Content type: Research

    Published on:

  22. The incidence of Merkel cell carcinoma (MCC), a rare form of skin cancer with a poor prognosis, has increased in Italy in recent decades. Avelumab, an anti-programmed death ligand 1 monoclonal antibody, is app...

    Authors: Giovanni Grignani, Vanna Chiarion Sileni, Carmine Pinto, Roberta Depenni, Nicola Fazio, Luca Galli, Dario Giuffrida, Carlo Carnaghi, Domenico Ciliberto, Domenico C. Corsi, Paola Queirolo, Elena Benincasa, Filippo Venturini, Gennaro Fazzi, Nuno Costa and Paolo Antonio Ascierto

    Citation: Journal of Translational Medicine 2021 19:70

    Content type: Research

    Published on:

  23. Clinical risk scores and machine learning models based on routine laboratory values could assist in automated early identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients at ri...

    Authors: Verena Schöning, Evangelia Liakoni, Christine Baumgartner, Aristomenis K. Exadaktylos, Wolf E. Hautz, Andrew Atkinson and Felix Hammann

    Citation: Journal of Translational Medicine 2021 19:56

    Content type: Research

    Published on:

  24. Recent preclinical data suggest that there may be therapeutic synergy between immune checkpoint blockade and inhibition of the coagulation cascade. Here, we investigate whether patients who received immune che...

    Authors: Paul Johannet, Amelia Sawyers, Nicholas Gulati, Douglas Donnelly, Samuel Kozloff, Yingzhi Qian, Alfredo Floristan, Eva Hernando, Judy Zhong and Iman Osman

    Citation: Journal of Translational Medicine 2021 19:47

    Content type: Research

    Published on:

  25. Epidermal growth factor receptor (EGFR) is frequently amplified or overexpressed in head and neck squamous cell carcinoma (HNSCC) and is a clinically validated target for the therapeutic antibody, cetuximab, i...

    Authors: Sean P. Korpela, Trista K. Hinz, Ayman Oweida, Jihye Kim, Jacob Calhoun, Robert Ferris, Raphael A. Nemenoff, Sana D. Karam, Eric T. Clambey and Lynn E. Heasley

    Citation: Journal of Translational Medicine 2021 19:43

    Content type: Research

    Published on:

  26. Studies carried out in vitro and in a mouse model have shown that BRAF inhibitors enhance the effects of IFN-α on BRAFV600E melanoma cells through the inhibition of ERK. Therefore, the combination of vemurafenib ...

    Authors: Ester Simeone, Giosuè Scognamiglio, Mariaelena Capone, Diana Giannarelli, Antonio M. Grimaldi, Domenico Mallardo, Gabriele Madonna, Marcello Curvietto, Assunta Esposito, Fabio Sandomenico, Francesco Sabbatino, Nicholas L. Bayless, Sarah Warren, SuFey Ong, Gerardo Botti, Keith T. Flaherty…

    Citation: Journal of Translational Medicine 2021 19:17

    Content type: Research

    Published on:

  27. Over the last few years, numerous clinical trials and real-world experience have provided a large amount of evidence demonstrating the potential for long-term survival with immunotherapy agents across various ...

    Authors: Paolo A. Ascierto, Lisa H. Butterfield, Katie Campbell, Bruno Daniele, Michael Dougan, Leisha A. Emens, Silvia Formenti, Filip Janku, Samir N. Khleif, Tomas Kirchhoff, Alessandro Morabito, Yana Najjar, Paul Nathan, Kunle Odunsi, Akash Patnaik, Chrystal M. Paulos…

    Citation: Journal of Translational Medicine 2021 19:13

    Content type: Meeting report

    Published on:

  28. The easy access to a quick diagnosis of coronavirus disease 2019 (COVID-19) is a key point to improve the management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to contain its spread. U...

    Authors: Leonardo Miscio, Antonio Olivieri, Francesco Labonia, Gianfranco De Feo, Paolo Chiodini, Giuseppe Portella, Luigi Atripaldi, Roberto Parrella, Rodolfo Conenna, Franco Maria Buonaguro, Ernesta Cavalcanti, Paolo Ascierto, Gerardo Botti and Attilio Bianchi

    Citation: Journal of Translational Medicine 2020 18:488

    Content type: Research

    Published on:

  29. The diagnosis of check-point inhibitor-related pneumonitis (CIP) relies on radiological and clinical patterns which are not specific and can mimic other conditions (cancer progression, infectious diseases or i...

    Authors: Sabino Strippoli, Livia Fucci, Antonio Negri, Daniela Putignano, Marco Luigi Cisternino, Gaetano Napoli, Ruggiero Filannino, Ivana De Risi, Angela Monica Sciacovelli and Michele Guida

    Citation: Journal of Translational Medicine 2020 18:473

    Content type: Research

    Published on:

  30. Cardiomyopathy is a common side effect of doxorubicin (DOX) chemotherapy. Despite intensive research efforts in the field, there is still no evidence available for routine cardioprotective prophylaxis to preve...

    Authors: Mária Lódi, Viktor Bánhegyi, Beáta Bódi, Alexandra Gyöngyösi, Árpád Kovács, Anita Árokszállási, Nazha Hamdani, Miklós Fagyas, István Édes, Zoltán Csanádi, István Czuriga, Zoltán Kisvárday, István Lekli, Péter Bai, Attila Tóth, Zoltán Papp…

    Citation: Journal of Translational Medicine 2020 18:470

    Content type: Research

    Published on:

  31. Information regarding characteristics and risk factors of COVID-19 amongst middle-aged (40–59 years) patients without comorbidities is scarce.

    Authors: Peng Wang, Jing Sha, Mei Meng, Cuiyan Wang, Qingchun Yao, Zhongfa Zhang, Wenqing Sun, Xingguang Wang, Guoqiang Qie, Xue Bai, Keke Liu and Yufeng Chu

    Citation: Journal of Translational Medicine 2020 18:461

    Content type: Research

    Published on:

  32. Ipilimumab and Nivolumab, targeting the molecules CTLA-4, PD-1, respectively,have shown efficacy against several types of cancer. Despite these results, only a small percentage of patients maintains a long-las...

    Authors: Paolo Marchetti, Andrea Botticelli, Antonio Paolo Ascierto, Giuseppe Curigliano and Diana Giannarelli

    Citation: Journal of Translational Medicine 2020 18:446

    Content type: Research

    Published on:

  33. Immune checkpoint inhibition (ICI) improves survival outcomes for patients with several types of cancer including metastatic melanoma (MM), but serious immune-related adverse events requiring intervention with...

    Authors: Nicholas Gulati, Douglas Donnelly, Yingzhi Qian, Una Moran, Paul Johannet, Judy Zhong and Iman Osman

    Citation: Journal of Translational Medicine 2020 18:430

    Content type: Research

    Published on:

  34. Interleukin-6 (IL-6) was proposed to be associated with the severity of coronavirus disease 2019 (COVID-19). The present study aimed to explore the kinetics of IL-6 levels, validate this association in COVID-1...

    Authors: Jing Zhang, Yiqun Hao, Wuling Ou, Fei Ming, Gai Liang, Yu Qian, Qian Cai, Shuang Dong, Sheng Hu, Weida Wang and Shaozhong Wei

    Citation: Journal of Translational Medicine 2020 18:406

    Content type: Research

    Published on:

  35. Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients.

    Authors: Francesco Perrone, Maria Carmela Piccirillo, Paolo Antonio Ascierto, Carlo Salvarani, Roberto Parrella, Anna Maria Marata, Patrizia Popoli, Laurenzia Ferraris, Massimiliano M. Marrocco-Trischitta, Diego Ripamonti, Francesca Binda, Paolo Bonfanti, Nicola Squillace, Francesco Castelli, Maria Lorenza Muiesan, Miriam Lichtner…

    Citation: Journal of Translational Medicine 2020 18:405

    Content type: Research

    Published on:

    The Correction to this article has been published in Journal of Translational Medicine 2021 19:442

  36. It is well established that thymidylate synthase inhibitors can cause cellular toxicity through uracil DNA glycosylase (UNG2)-dependent pathways. Additionally, thymidylate synthase inhibitors and HDAC inhibito...

    Authors: Meredith S. Showler and Brian P. Weiser

    Citation: Journal of Translational Medicine 2020 18:377

    Content type: Commentary

    Published on:

  37. More than seven months into the coronavirus disease -19 (COVID-19) pandemic, infection from the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to over 21.2 million cases and resulted in o...

    Authors: Maurice A. Canham, John D. M. Campbell and Joanne C. Mountford

    Citation: Journal of Translational Medicine 2020 18:359

    Content type: Review

    Published on:

  38. Severe COVID-19 infection results in a systemic inflammatory response (SIRS). This SIRS response shares similarities to the changes observed during the peri-operative period that are recognised to be associate...

    Authors: Donogh Maguire, Marylynne Woods, Conor Richards, Ross Dolan, Jesse Wilson Veitch, Wei M. J. Sim, Olivia E. H. Kemmett, David C. Milton, Sophie L. W. Randall, Ly D. Bui, Nicola Goldmann, Allan Cameron, Barry Laird, Dinesh Talwar, Ian Godber, Alan Davidson…

    Citation: Journal of Translational Medicine 2020 18:354

    Content type: Research

    Published on:

  39. Unresectable or metastatic vulvar cancer has relatively poor outcomes despite chemotherapy-sensitized radiation therapy and combination cytotoxic therapy. Despite the virus-associated and immunogenic nature of...

    Authors: Oladapo Yeku, Andrea L. Russo, Hang Lee and David Spriggs

    Citation: Journal of Translational Medicine 2020 18:350

    Content type: Protocol

    Published on:

  40. The melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, ...

    Authors: Paolo A. Ascierto, Igor Puzanov, Sanjiv S. Agarwala, Christian Blank, Richard D. Carvajal, Sandra Demaria, Reinhard Dummer, Marc Ernstoff, Soldano Ferrone, Bernard A. Fox, Thomas F. Gajewski, Claus Garbe, Patrick Hwu, Roger S. Lo, Georgina V. Long, Jason J. Luke…

    Citation: Journal of Translational Medicine 2020 18:346

    Content type: Meeting report

    Published on:

  41. Antibody based cancer therapies have achieved convincing success rates combining enhanced tumor specificity and reduced side effects in patients. Trastuzumab that targets the human epidermal growth factor rela...

    Authors: Anja Kathrin Wege, Nicole Kirchhammer, Linda Veronique Kazandjian, Sandra Prassl, Michael Brandt, Gerhard Piendl, Olaf Ortmann, Stephan Fischer and Gero Brockhoff

    Citation: Journal of Translational Medicine 2020 18:316

    Content type: Research

    Published on:

  42. In the rapidly evolving coronavirus disease 2019 (COVID-19) outbreak, inherent literature has been increasing at an impressive rate. Such a dynamic scenario imposes the necessity to define a new framework for ...

    Authors: Maddalena Barba, Eriseld Krasniqi, Gennaro Ciliberto and Patrizia Vici

    Citation: Journal of Translational Medicine 2020 18:315

    Content type: Commentary

    Published on:

  43. Necrotizing enterocolitis (NEC) is one of the most severe complications in very preterm infants, but there are currently no accepted methods to prevent NEC. Studies have shown that erythropoietin (EPO) has the...

    Authors: Yong Wang, Juan Song, Huiqing Sun, Falin Xu, Kenan Li, Chunxia Nie, Xiaoli Zhang, Xirui Peng, Lei Xia, Ziyun Shen, Xiao Yuan, Shan Zhang, Xue Ding, Yaodong Zhang, Wenqing Kang, Liling Qian…

    Citation: Journal of Translational Medicine 2020 18:308

    Content type: Research

    Published on:

  44. We sought to identify patient subgroups with distinct postprogression overall survival (ppOS) outcomes and investigate the impact of original treatment assignment and initial postprogression treatment (ppRx) o...

    Authors: Paolo A. Ascierto, Antoni Ribas, James Larkin, Grant A. McArthur, Karl D. Lewis, Axel Hauschild, Keith T. Flaherty, Edward McKenna, Qian Zhu, Yong Mun and Brigitte Dréno

    Citation: Journal of Translational Medicine 2020 18:294

    Content type: Research

    Published on:

  45. Immunotherapy with checkpoint inhibitors (CPI) targeting PD-1 or CTLA-4 has emerged as an important treatment modality for several cancer forms. In hormone receptor positive breast cancer (HR + BC), this thera...

    Authors: J. A. Kyte, N. K. Andresen, H. G. Russnes, S. Ø. Fretland, R. S. Falk, O. C. Lingjærde and B. Naume

    Citation: Journal of Translational Medicine 2020 18:269

    Content type: Protocol

    Published on:

  46. The recent global pandemic has placed a high priority on identifying drugs to prevent or lessen clinical infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), caused by Coronavirus disease...

    Authors: Jason Kim, Jenny Zhang, Yoonjeong Cha, Sarah Kolitz, Jason Funt, Renan Escalante Chong, Scott Barrett, Rebecca Kusko, Ben Zeskind and Howard Kaufman

    Citation: Journal of Translational Medicine 2020 18:257

    Content type: Research

    Published on:

  47. Immunotherapy with checkpoint inhibitors (CI) represents an important novel development in cancer treatment. Metastatic triple-negative breast cancer (mTNBC) is incurable, with a median survival of only ~ 13 m...

    Authors: J. A. Kyte, A. Røssevold, R. S. Falk and B. Naume

    Citation: Journal of Translational Medicine 2020 18:252

    Content type: Protocol

    Published on:

Annual Journal Metrics